,7 for the DESIR Study Group 2 * Recently, case-control studies demonstrated that a TCF7L2 (transcription factor 7-like 2 gene) noncoding variant (rs7903146 T at-risk allele) was strongly associated with an increased risk of type 2 diabetes. However, the predictive value of this marker in a nonselected general population remains unknown. In this study, our aim was to assess the contribution of this variant to the prevalence and incidence of hyperglycemia (type 2 diabetes and impaired fasting glucose) and insulin regulation in a 9-year prospective study of 4,976 middle-aged participants in the French DESIR (Data from an Epidemiological Study on the Insulin Resistance Syndrome) cohort. Our data support previous studies associating the T at-risk allele with a higher prevalence of hyperglycemia at baseline (P ‫؍‬ 0.049) and a higher incidence of hyperglycemia after 9 years of follow-up (P ‫؍‬ 0.014). The population-attributable risk to develop hyperglycemia due to the T at-risk allele was estimated to be 10.4% at the end of the prospective study. The most likely inheritance model was found to be additive (P ‫؍‬ 0.002) rather than deviating from linearity (P ‫؍‬ 0.098). An increase in the incidence of hyperglycemia was confirmed by survival analyses among C/C, C/T, and T/T carriers during the 9 years of follow-up (P ‫؍‬ 0.028 by log-rank test). Interestingly, in control individuals, there was weak evidence of association of the T at-risk allele with reduced fasting insulin levels and insulin secretion index (homeostasis model assessment of ␤-cell function) in control individuals. We conclude that the TCF7L2 T at-risk allele variation (rs7903146) predicts hyperglycemia incidence in a general French population, possibly through a deleterious effect on insulin secretion. Diabetes 55: 3189 -3192, 2006
R
ecently, a strong association was found in individuals of European origin between type 2 diabetes and the DG10S478 microsatellite within intron 3 of the transcription factor 7-like 2 (TCF7L2) gene (1) . The rs7903146 T at-risk allele variation was then strongly correlated with this microsatellite (r 2 ϭ 0.78), and it was shown to be the allele most associated with type 2 diabetes (relative risk 1.54, P ϭ 2.1 ϫ 10 Ϫ17 ). The potentially large contribution of this gene variant to type 2 diabetes risk was further confirmed in 2,367 type 2 diabetic participants and 2,499 control subjects of FrenchCaucasian descent (odds ratio [OR] 1.69 [95% CI 1.55-1.83], P ϭ 6.0 ϫ 10 Ϫ35 ) (2) . In nonobese type 2 diabetic participants, the association was even stronger (1.89 [1.72-2.09], P ϭ 2.1 ϫ 10
Ϫ38
), suggesting that TCF7L2 may contribute to insulin secretion defects rather than to insulin resistance resulting from adiposity. In these type 2 diabetic participants, the T at-risk allele was also significantly associated with lower BMI and younger age at diagnosis. In control individuals, however, no association with any metabolic parameter was found, supporting the hypothesis that the effects of TCF7L2 on type 2 diabetes risk are not mediated by an interaction with adiposity, as previously described for another type 2 diabetes susceptibility gene (3) .
Although large scale case-control studies are very sensitive in detecting genetic effects, they are not sufficient to evaluate the true contribution of disease-associated genes in nonselected general populations (4) . Therefore, the objective of this study was to examine whether the T at-risk allele predicted hyperglycemia (type 2 diabetes and impaired fasting glucose [IFG] In the studied samples, rs7903146 genotypic distributions did not deviate from the Hardy-Weinberg equilibrium. Genotypic/phenotypic data were analyzed by comparing relevant quantitative traits in three different ways. At baseline (A1: prevalence analysis), we compared the control subjects (n ϭ 4,434) with hyperglycemic participants (n ϭ 542). Individuals who were control subjects at baseline were then reanalyzed after 9 years of follow-up (A2: incidence analysis), and we compared those who remained nonaffected at the end of the study (n ϭ 2,925) with the incident hyperglycemic participants (n ϭ 460). In the third analysis (A3: prospective analysis), individuals who remained nonaffected after 9 years of follow-up (n ϭ 2,925) were compared with all hyperglycemic participants (both baseline and incident cases, n ϭ 1,002). In all three analyses (A1-A3), we found that the T at-risk allele was associated with hyperglycemia risk (OR 1.14 [95% CI 1.00 - . At baseline, the proportions of type 2 diabetes among hyperglycemic participants were 26% for C/C, 24% for C/T, and 30% for T/T carriers, respectively. After 9 years of followup, the proportions of type 2 diabetes among hyperglycemic participants were 31% for C/C, 31% for C/T, and 39% for T/T carriers, respectively. During 9 years of follow-up, among individuals with IFG, 21% of C/C, 27.0% of C/T, and 34% of T/T carriers converted to type 2 diabetes. While more men than women had type 2 diabetes and IFG, no statistical heterogeneity was found between the ORs for men and women (supplementary Table 2 of the online appendix). The population-attributable risk (PAR) to develop hyperglycemia and type 2 diabetes resulting from the T at-risk allele was 10.4 and 13.3%, respectively, at the end of the prospective study (A3 analysis). At the end of the follow-up (A3 analysis), the most likely inheritance model was found to be additive (P ϭ 0.002), with no deviation from linearity (P ϭ 0.098). An increase in hyperglycemia incidence (A2 analysis) was confirmed by survival analyses among C/C, C/T, and T/T carriers during the 9 years of follow-up (hazard ratio 1.21 [95% CI 1.05-1.39], P ϭ 0.008) ( Fig. 1) . At the end of the study, the prevalences of hyperglycemia (A3 analysis) were found to be 23% for C/C, 27% for C/T, and 30% for T/T carriers, respectively (Table 1 ).
Quantitative trait analyses were then performed in control individuals (Table 2) . At baseline (A1 analysis), only two traits differed significantly; between homozygotes C/C and T/T, we found a 0.07 decrease in ln(fasting insulinemia) (3.68 Ϯ 0.51 for C/C, 3.66 Ϯ 0.51 for C/T, and 3.61 Ϯ 0.53 for T/T; P ϭ 0.04) and a 0. The genotypic distributions were in agreement with Hardy-Weinberg equilibrium. A1: At baseline, all participants. A2: Control: participants followed 9 years and remaining normoglycemic over the 9 years. HG: incident cases of hyperglycemia over the 9 years. A3: Control: participants followed 9 years and remaining normoglycemic over the 9 years. HG: participants hyperglycemic at baseline and incident cases of hyperglycemia.
TCF7L2 AND PROSPECTIVE RISK OF HYPERGLYCEMIA
applied, and none of the P values remained significant. In participants who remained nonaffected after 9 years of follow-up (A2 and A3 analyses), none of the analyzed traits were significantly different among the three genotypes. No significant association was found within control subjects with any other quantitative traits such as BMI, fasting glucose, HOMA-IR, triglycerides, or total, HDL, or LDL cholesterol. Numerous gene variants have been associated with type 2 diabetes, but information about their predictive value has been hampered, as very few variants have been assessed in long large-scale prospective observational studies (5-7). The TCF7L2 rs7903146 T at-risk allele has been strongly associated with type 2 diabetes in several populations of European origin (1,2). The minor allelic frequency is quite high (ϳ30%) in these populations, and it confers a relative risk ranging between 1.5 and 1.9, with an attributable risk ranging between 20 and 35% (1,2). The major interest of the present study is to provide further information on this gene variant for both hyperglycemia prevalence and incidence during a 9-year follow-up of a middle-aged cohort from a French general population. However, the ORs (1.2-1.3) and PARs (10.4% for hyperglycemia and 13.3% for type 2 diabetes) are lower in the DESIR study than in French case-control cohorts. The PAR is probably better estimated in a general population than in control subjects from case-control studies. However, the ORs in DESIR correspond to only 1 decade of exposure, whereas the case-control analysis gives a more composite value of a lifetime exposure. Although the allelic ORs are substantially lower than in other studies, the CIs of the genotypic ORs (C/C versus C/T and C/T versus TT, one being the wild-type allele) overlap with previously published estimations (1,2). An explanation for these differences may lie in the physiological role of the TCF7L2 transcription factor in glucose homeostasis. It has been suggested that intestinal proglucagon gene expression may be regulated by the Wnt/TCF7L2 pathway in enteroendocrine cells (8) , and we found that TCF7L2 was also expressed in human ␤-cells (2) . In the present study, we found only weak evidence of association with limited reduction of fasting insulin levels and HOMA-B values in control subjects during the 9 years of follow-up (no post-glucose load data were available in the DESIR study), suggesting a potential impact of the T at-risk allele on insulin secretion. After simple Bonferroni corrections, no P values remained significant. However, the pathogenic traits monitored during our study (BMI, insulin, glucose, and lipid traits) are not independent, and they have been shown to be related in type 2 diabetes (9); thus, it is unlikely that the effect of a variant on these parameters would occur only by chance. The results need to be confirmed in other cohorts in order to clarify the physiological consequences of the rs79013146 T at-risk allele. Interestingly, neither BMI nor any quantitative traits related to atherosclerosis were found to be associated with the T at-risk allele, which makes it unlikely that the TCF7L2 diabetogenic effect directly involves insulin sensitivity or fat deposition.
In conclusion, this study shows that the TCF7L2 T at-risk allele variation (rs7903146) predicts hyperglycemia in a nonselected, prospectively followed, general, middleaged, French population. This is probably due to a continuous impairment in insulin secretion. Further studies should be directed at determining the molecular and physiological mechanisms by which TCF7L2 contributes to glucose homeostasis and type 2 diabetes development.
RESEARCH DESIGN AND METHODS
The study population (men and women aged between 30 and 65 years [equal amounts of men and women by 5-year age-groups]) participated in the cohort for the DESIR, a 9-year follow-up study that aims to clarify the development of the insulin resistance syndrome (10) . Participants were recruited from volunteers insured by the French social security system, which offers 5-yearly periodic health examinations free of charge. They came from 10 health examination centers in the western-central part of France. All participants signed an informed consent. The protocol was approved by the ethics committee at Bicê tre Hospital. Pregnant women, those who did not want their results communicated to their general practitioners, those expecting to shift from the geographical region of the study, and those already participating in another study were excluded. For the 5,212 individuals included in the study, there were examinations every 3 years, and 3,981 (76%) were examined at 9 years. A total of 4,976 participants, genotyped for the rs7903146 T at-risk allele, had data available at baseline. Among them, 4,434 participants were normoglycemic, of whom 3,927 (mean age at recruitment 47 Ϯ 10 years) could be followed for type 2 diabetes and IFG during a 9-year period (response rate 0.89). Three classes of glycemic status were defined according to 1997 American Diabetes Association criteria: normoglycemia, fasting plasma glucose Ͻ6.1 mmol/l; IFG, fasting plasma glucose between 6.1 and 6.9 mmol/l; and type 2 diabetes, fasting plasma glucose Ն7.0 mmol/l and/or treatment by antidiabetes agents. Participants were classified as hyperglycemic if they had either type 2 diabetes or IFG (6) . The mean BMI was 24.12 Ϯ 3.40 kg/m 2 for control subjects, 26.87 Ϯ 4.12 kg/m 2 for hyperglycemic (IFG plus type 2 diabetes) participants, and 28.44 Ϯ 4.34 kg/m 2 for type 2 diabetic participants. Quantitative trait measures. Weight, height, and waist circumferences were measured by trained personnel, and BMI (weight in kilograms divided by the square of height in meters) was calculated. Venous blood samples were collected in the morning after participants had fasted 12 h. Fasting plasma glucose was assayed by the glucose oxidase method applied to fluoro-oxalated plasma, using a Technicon RA 1000 (Bayer, Puteaux, France) or a Kone 
